FY2025 EPS Estimate for Olema Pharmaceuticals Cut by Analyst

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) – Lifesci Capital reduced their FY2025 earnings estimates for shares of Olema Pharmaceuticals in a note issued to investors on Wednesday, March 19th. Lifesci Capital analyst S. Slutsky now forecasts that the company will earn ($2.28) per share for the year, down from their prior forecast of ($2.12). The consensus estimate for Olema Pharmaceuticals’ current full-year earnings is ($2.33) per share.

Olema Pharmaceuticals (NASDAQ:OLMA) last released its quarterly earnings data on Tuesday, March 18th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.12.

OLMA has been the topic of a number of other research reports. HC Wainwright reissued a “buy” rating and set a $30.00 price objective on shares of Olema Pharmaceuticals in a research report on Wednesday. Oppenheimer restated an “outperform” rating and issued a $25.00 target price (down previously from $30.00) on shares of Olema Pharmaceuticals in a report on Wednesday.

Olema Pharmaceuticals Price Performance

OLMA stock opened at $4.23 on Friday. The stock has a market capitalization of $242.37 million, a PE ratio of -1.93 and a beta of 2.11. The company’s 50-day moving average is $5.09 and its 200-day moving average is $8.35. Olema Pharmaceuticals has a 1 year low of $3.94 and a 1 year high of $16.62.

Hedge Funds Weigh In On Olema Pharmaceuticals

Several hedge funds have recently modified their holdings of the company. Bain Capital Life Sciences Investors LLC bought a new position in shares of Olema Pharmaceuticals during the 4th quarter worth approximately $43,551,000. Paradigm Biocapital Advisors LP lifted its position in shares of Olema Pharmaceuticals by 32.7% during the 4th quarter. Paradigm Biocapital Advisors LP now owns 7,304,970 shares of the company’s stock worth $42,588,000 after buying an additional 1,801,370 shares in the last quarter. Point72 Asset Management L.P. lifted its position in shares of Olema Pharmaceuticals by 14.8% during the 3rd quarter. Point72 Asset Management L.P. now owns 3,687,374 shares of the company’s stock worth $44,027,000 after buying an additional 475,447 shares in the last quarter. MPM Bioimpact LLC lifted its position in shares of Olema Pharmaceuticals by 8.7% during the 4th quarter. MPM Bioimpact LLC now owns 2,912,550 shares of the company’s stock worth $16,980,000 after buying an additional 231,954 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in shares of Olema Pharmaceuticals by 6.0% during the 4th quarter. Vanguard Group Inc. now owns 2,685,009 shares of the company’s stock worth $15,654,000 after buying an additional 152,117 shares in the last quarter. Institutional investors own 91.78% of the company’s stock.

Insider Buying and Selling

In other news, major shareholder Bain Capital Life Sciences Inv bought 300,000 shares of the company’s stock in a transaction on Wednesday, January 8th. The shares were purchased at an average price of $5.76 per share, with a total value of $1,728,000.00. Following the transaction, the insider now directly owns 7,800,000 shares in the company, valued at $44,928,000. This represents a 4.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 19.40% of the stock is currently owned by company insiders.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.